• Loading stock data...
PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » General » PetLife Announces its All-natural ‘Cancer Cocktail’ With Applicability to Pet and Human Markets

PetLife Announces its All-natural ‘Cancer Cocktail’ With Applicability to Pet and Human Markets

Randy Whitney by Randy Whitney
April 26, 2019
in General, Medical
4 min read
28
0

The Company may be the first to offer an all-natural ‘cancer cocktail’ combining the therapeutic benefits of the plant and animal kingdoms

PR Newswire, PTLF

HANCOCK, Maryland, June 14, 2017

HANCOCK, Maryland, June 14, 2017 /PRNewswire/ —

PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, reports on its solution to the ever increasing problem of drug resistance and high toxicity in the treatment of cancer in pets and humans. Each year, in the U.S. alone, more than eleven million cases of cancer in dogs and cats are reported, a number that continues to increase annually.

PetLife’s new patent-pending formulation has created a ‘cancer cocktail’ combining both Blue Scorpion Venom Chlorotoxin with plant-based phytonutrients. Preliminary testing has shown inhibition against certain cancer cell line studies without toxicity. Across the world, researchers have recognized that many cells which cause disease, have the ability to become resistant to treatment when only one drug is used. Combination therapy is increasing, recommended for the treatment of both neoplastic (cancer) and infectious disease. The ‘HIV Cocktail’, which changed the world’s approach to the treatment of HIV, is a similar approach comparison. PetLife’s new ‘cancer cocktail’ may prove to be the non-toxic alternative to the harmful and sometimes deadly side effects of radiation and chemotherapy. The patent pending formulation of PetLife’s new ‘cancer cocktail’ has the curious ability to bind selectively to cancer cells and inhibit their growth demonstrating little to no side effects to the patient.

For hundreds, if not thousands of years, plant-based medicinals have formed the foundation of therapeutic treatment in the Chinese, Native American and Ayurvedic traditions. More recently, scientists have discovered the mode of action of many of these therapies. In many cases, the chemical compounds have been manipulated or synthesized to create new chemical entitles (“NCE”). Along with the creation of NCEs comes the inherent risk of unintended consequences and adverse reactions. By maintaining an all-natural formulation, PetLife intends to capture the therapeutic benefit of plant-based therapy without the creation of any unintended consequences. Our team has identified certain phytonutrients which can work synergistically with Blue Scorpion Venom for inhibition of cancer cell growth.

“Our new formulation, RX002CxN, will become the basis of PetLife Pharmaceutical’s new product portfolio, Vitalzul[TM], a novel treatment option for the treatment of cancer and potentially other indications. The low toxicity of our formulation gives additional benefit. Given the comparative biology of animals and humans, it is our hope that success in treatment of cancer in animals will lead to similar results in humans. Our new formulation has been designed with both human and animal applications in mind. Once testing is completed, the Company will strategically determine the best course of development in both the pet and human markets,” stated Dr. Vivekananda Ramana, Chief Medical Officer of the Company.

“This groundbreaking, patent pending biotechnology will serve as the core ingredient in our pharma product Vitalzul[TM] once we complete the much anticipated FDA trials. It is well known that animal research and studies are the foundation of human applications. Our first goal is to complete the successful testing, FDA application and commercialization for the benefit of animals. Then, we will move aggressively in expanding our research in the human arena, where we anticipate strong interest from industry leaders,” added Dr. Salvagno.

About PetLife Pharmaceutical

PetLife Pharmaceuticals, Inc. (PTLF) (http://www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife’s mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company’s first product, Vitalzul[TM], is currently in testing. Vitalzul[TM]‘s active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications. PetLife’s acquired brand, Dr. Geoff’s Real Food for Pets will launch in 2017. PetLife Scorpion Ranch™ will break ground in 2017. PetLife anticipates incorporating Vitalzul[TM] in a new and advanced therapeutic pet food line in 2019.

Forward looking statement:

This press release contains certain “forward-looking statements,” as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. The economic, competitive, governmental, technological and other factors identified in the Company’s previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Tags: cancermedicationsnutraceuticalsPetLife PharmaceuticalspetsPTLFveterinary
Randy Whitney

Randy Whitney

Randy is a marketing specialist with experience creating content for sports and real estate in New York City. He has written for Major League Baseball and Cut4 as well as contributed creatively to the growth and development of startups around the country.

Related Posts

Regeneron buy back shares from Sanofi
Medical

Regeneron to buy back $5 billion shares from Sanofi

May 25, 2020
137
China Opposed U.S. Audit Plans
General

China Opposed U.S. Audit Plans

May 24, 2020
138
JetBlue gives 100,000 free flights to healthcare workers.
General

JetBlue Announces ‘JetBlue Healthcare Hero’ Program — Giving Away 100,000 Free Flights to Healthcare Workers

May 6, 2020
172
Trans-Pacific flights are most likely to be affected the most with demand declining up to 80% due to the pandemic.
General

American Airlines is looking into canceling up to 60% of its summer schedules as the pandemic continues to push demand down

April 2, 2020
139
Louisiana tops the list of states with the most number of increase in unemployment insurance claims because of the COVID-19 pandemic.
General

Here are the states that suffered the most unemployment due to COVID-19 pandemic

April 2, 2020
153
Kynikos Associates founder warns investors against ‘virus stocks’
General

Kynikos Associates founder warns investors against ‘virus stocks’

April 2, 2020
179
Currently Playing

Subscribe To Our Newsletter

Ad

PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2020 PublicWire.com

Navigate Site

  • About
  • #96576 (no title)
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • #370 (no title)

© Copyright 2020 PublicWire.com

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Public Wire Logo

Hello please subscribe to our newsletter to get up to date news weekly!

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.